bpc 157 clinical trials status 2025 FDA's Review Of Peptides Signals A Growing Public Health Challenge Peptides get their regulatory close-up

Dropout rates in some studies reach up to 30% 95% of trials do not compensate participants beyond basic expense reimbursement Compensation levels can vary significantly between sites, even within the same study These factors have a direct impact on recruitment speed, retention, and data quality

References 1 FDA Wegovy (semaglutide) Prescribing InformationFDA-approved labeling for the standalone semaglutide molecule (GLP-1 receptor agonist) for chronic weight management

For the broader picture of which peptides already have FDA approval, see our FDA Approved Peptides List 2026

Ready when you are BPC-157 The body protection compound for accelerated healing From $169/mo compounded by a licensed 503A pharmacy, dispensed only after provider review

Healing primarily occurs through primary intention, where the wound edges fuse with minimal granulation tissue formation

Cagrilintide Dosage for Diabetes Research Cagrilintide has also been studied for its ability to manage blood sugar in patients with type 2 diabetes (T2D) but only when used in combination with semaglutide